Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03726788
Other study ID # RC-P0037
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 2019
Est. completion date April 2022

Study information

Verified date March 2019
Source Lille Catholic University
Contact Amélie Lansiaux, MD PhD
Phone 03 20 22 52 69
Email lansiaux.amelie@ghicl.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We believe we can demonstrate a link between the analgesic action of intra-articular injection of botulinum toxin and synovial inflammation by Dynamic Contrast Enhancement (DCE) perfusion Magnetic Resonance Imaging (MRI).


Description:

Knee osteoarthritis is one of the most common causes of joint pain and functional disability in the general population.

Intra-articular infiltrations of corticoids are indicated for painful crisis especially if accompanied of effusion. However, this effect lasts only 2 weeks.

Given the lack of effective long-term medical-infiltrative treatment, we believe that botulinum toxin type A could be used by its direct action on mediators of neuro-gene inflammation at the joint level and its indirect medullary action by retrograde migration.

To date, 2 published randomized controlled trials and one unpublished Phase Ib clinical trial have shown that botulinum toxin injected intraarticularly improves pain and functionality in gonarthrosis.

Dynamic Contrast Enhancement (DCE) Magnetic Resonance Imaging (MRI) demonstrated the correlation between synovial inflammation and pain in gonarthrosis in a cohort of 454 subjects. It has also made it possible, via the monitoring of synovial inflammation, to demonstrate the efficacy of treatments in patients suffering from rheumatoid arthritis in the early phase, juvenile chronic arthritis or osteoarthritis.

DCE MRI perfusion therefore appears here as the technique of choice to follow the evolution of synovial inflammation after botulinum toxin injection in patients with symptomatic gonarthrosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 105
Est. completion date April 2022
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- Presenting gonarthrosis of degenerative origin, Kellgren/Lawrence Radiological Stage I to III, with a maturity of more than 18 months

- With pain intensity greater than or equal to 50/100 on an VAS

- In case of bilateral gonarthrosis, the VAS of the contralateral knee must be less than or equal to 30/100

- Presenting a failure of conventional per os treatments (non-steroidal anti-inflammatory drugs, analgesics)

- Affiliated with a social security scheme

- For women of childbearing age:

- effective contraception for the duration of the study

Exclusion Criteria:

- Patient presenting at the time of the inclusion visit: an inflammatory attack, septic or inflammatory arthritis, a generalized infectious episode in progress

- Local or regional local skin lesion

- Need of an arthroplasty within the next 12 months

- Having received corticosteroids or other molecules in intra-articular infiltration in the last 6 months

- History of traumatic knee injury (bone injury in the past 24 months), bone, ligament or meniscal surgery in the past 24 months

- History of disabling peripheral nerve injury

- Severe bleeding disorders, anticoagulant treatment in progress or double antiplatelet aggregation

- BMI > 35 kg/m2

- Coxarthrosis with projected knee pain

- Pregnant or breastfeeding woman

- Patient under guardianship and protection of justice

- Allergy/contraindication to botulinum toxin type A, corticoids

- Usual contraindication to MRI

- Allergy to the contrast product

Study Design


Intervention

Drug:
Botulinum Toxin Type A 100U
one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
Botulinum Toxin Type A 200U
one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
Triamcinolone Hexacetonide Inj Susp 20 MG/ML
one intra-articular injection of 2 ml Triamcinolone Hexacetonide

Locations

Country Name City State
France Lille Catholic University Lille

Sponsors (2)

Lead Sponsor Collaborator
Lille Catholic University Allergan

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assesment of vascularization by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) according to the % Area Under the Curve (AUC) of perfusion value one month post-injection
Secondary Pain analysis by the visual analogue scale (VAS) Evolution kinetics of daily pain collected during the first 3 months post-injection allowing to deduce the onset and duration of analgesic efficacy in number of days. The pain VAS is a continuous scale comprised of a horizontal line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme: "no pain" (score of 0) and "pain as bad as it could be" (score of 100 [100-mm scale]) during the first 3 months after injection
Secondary Joint amplitude measured by goniometry To measure range of motion of the knee at 1, 3, 6 month post-injection
Secondary Western Ontario McMaster University Osteoarthritis (WOMAC) Index An arthritic pain scoring system ranging from 0-no pain/disability to 100-most severe pain/disability at 1, 3, 6 month post-injection
Secondary Two minutes walk This test measure the distance walked in two minutes at 1, 3, 6 month post-injection
Secondary Frequency of consumption of analgesics at 1, 3, 6 month post-injection
Secondary Amount of consumption of analgesics at 1, 3, 6 month post-injection
See also
  Status Clinical Trial Phase
Recruiting NCT03785171 - Predicative Value of Multimodal MRI in Moyamoya Disease
Active, not recruiting NCT01956409 - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Phase 4
Completed NCT01660841 - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging Phase 3
Recruiting NCT03635619 - The Application of 3T MRI in Esophageal Cancer
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Recruiting NCT04850001 - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting NCT05498623 - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting NCT04996615 - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Completed NCT02540967 - Drug Use Investigation of Gadovist.
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT02567318 - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? N/A
Recruiting NCT02834585 - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) N/A
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer N/A
Completed NCT01223404 - Nicotinic Modulation of the Default Network N/A